Bevasiranib sodium
Bevasiranib sodium is a small interfering RNA (siRNA) therapeutic agent designed to inhibit vascular endothelial growth factor (VEGF) expression. By silencing VEGF genes, it is applied in research models of choroidal neovascularization to study mechanisms and potential treatments for wet age-related macular degeneration, utilizing both in vitro and in vivo experimental approaches.
Product Specifications
CAS Number
849758-52-7
Field of Research
Cardiovascular Research, Signal Transduction
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-54305R-BF405-TR 20 µL
Huntingtin Recombinant Antibody, AbBy Fluor™ 405 Conjugated
Sign In for Pricing
View Details 
C9895 96 Tests
Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 (RPN2) Porcine ELISA Kit
Sign In for Pricing
View Details 
MBS6362549-01 0.1 mL
VGLL2, NT (VGLL2, VITO1, Transcription cofactor vestigial-like protein 2, Protein VITO1) (MaxLight 490)
Sign In for Pricing
View Details 
MBS6362549-02 5x 0.1 mL
VGLL2, NT (VGLL2, VITO1, Transcription cofactor vestigial-like protein 2, Protein VITO1) (MaxLight 490)
Sign In for Pricing
View Details